FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum

AJANTPHARM Share Price Discussion

Ajanta Pharma Ltd.
Sector: Pharmaceuticals and health care
... Read more
AJANTPHARM Long Term Analysts Rating
4.5/5 (4 Ratings)
AJANTPHARM Share Price *
1,185 +5.15 (0.44%)
* (quote may be delayed)

Find answers to all your questions on live AJANTPHARM message board: Is AJANTPHARM buy or sell? Should I buy AJANTPHARM shares? Why are AJANTPHARM shares falling? Should I invest in AJANTPHARM stock?


You can also check AJANTPHARM share price target recommended by brokerages.

AJANTPHARM Discussion Forum


AJANTAPHARMA
GOOD FOR BUY
CMP 1205
WITH SUPPORT 1190
Like
reply
Reply (1)
Latest replies
STOCK MARKET TIPS @MarketBuddy
Yesterday 3:30 PM

AJANTAPHARMA 1210🔥
@stocktrendr • Reputation: 159

Ajanta Pharma gets US FDA nod for Valganciclovir Hydrochloride. It is used to treat CMV Retinitis in people with HIV Diseases
Like
reply
Reply

💠💠
YOUR FREE EQUITY CASH CALL FOR THIS FORUM TODAY:
BUY AJANTA PHARMA AT THE VERY BEGINING
STRICT STOP LOSS - 1067.40
1ST TARGET - 1090
2ND TARGET - 1095
3RD TARGET - 1098
## GO WITH SAFER QUANTITY ##
Disclaimer: All my Views/Suggestions/Calls are for Education Purpose Only. Pl...
Read more...
Like
reply
Reply

BOOK PART BTST AJANTPHARM AT @1025
Like
reply
Reply
@barunvirat • Reputation: 40

AJANTAPHARMA✅ BUY ABOVE 980.5 , 978, TG 990+++
Like
reply
Reply

*BUY AJANTA PHARMA ABOVE 1000(ONLY CASH)*
Like
reply
Reply
@sagar7777 • Reputation: 868

Sell Ajanta Pharma 1000-995 SL 1020 Target 990 , 980
Like
reply
Reply
@hidden • Reputation: 3,200

Strides Shasun, Ajanta Pharma pass USFDA#39;s ranitidine impurity test The lab results also found that the NDMA impurity in ranitidine drugs sold by Dr Reddy’s and Aurobindo Pharma, Sanofi in beyond permissible limits.
Like
reply
Reply
@umanath • Reputation: 563

AJANTPHARM - 426439

Like
reply
Reply

India's Ajanta Pharma Sept-Quarter Profit Falls
SEPT-QUARTER NET PROFIT 1.16 BILLION RUPEES VERSUS 1.25 BILLION RUPEES YEAR AGO
SEPT-QUARTER REVENUE FROM OPERATIONS 6.43 BILLION RUPEES VERSUS 5.44 BILLION RUPEES YEAR AGO
1
reply
Reply
@100billionclub • Reputation: 3,836
santosh gupta in AJANTPHARM
BUY AJANTPHARM ABV 1026

ONCE EXIT LONG IN AJANTPHARM AT 1037. BOT AT 1026. NSE
Like
reply
Reply
@100billionclub • Reputation: 3,836

BUY AJANTPHARM ABV 1026
Like
reply
Reply

AJANTPHARM - chart - 377319
EOD chart
1
reply
Reply
@newsbot • Reputation: 1,933
GSK suspends Ranitidine distribution in India, regulators seek drug testing data from pharma cos
Sources within pharma industry told Moneycontrol that Dr Reddy’s and Saraca Laboratories are two big suppliers of the Ranitidine active pharmaceutical ingredient (API) globally, from which most other companies source the API to formulate the drug.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 1,933
link
Avoid Aurobindo Pharma: Pritesh Mehta
Pritesh Mehta of IIFL is of the view that one may avoid Aurobindo Pharma.
Moneycontrol
Like
reply
Reply
@devthakur • Reputation: 0
Dev Thakur in AJANTPHARM
AJANTAPHARM BUY AT 1053 TGT 1060

Tgt done 1062. 15highh
Like
reply
Reply
@devthakur • Reputation: 0

AJANTAPHARM BUY AT 1053
TGT 1060
Like
reply
Reply
@newsbot • Reputation: 1,933
SBI, Ceat among 4 stocks brokerages are betting on for handsome gains — Here's why
SMC Global Securities has a buy on Ajanta Pharma and Can Fin Homes while Choice Broking has buy on State Bank of India.
Moneycontrol
Like
reply
Reply
@devthakur • Reputation: 0
Dev Thakur in AJANTPHARM
AJANTAPHARM BUY AT 1035 SL 1030 TGT 1040/45

High 1055... Book the full profit
Jackpot call
Like
reply
Reply
@devthakur • Reputation: 0

AJANTAPHARM BUY AT 1035
SL 1030
TGT 1040/45
Like
reply
Reply

AJANTPHARM - chart - 347941
Ajantpharm weekly chart. Falling wedge pattern on the chart. Staying above trendline will give good move.
Like
reply
Reply
@tipupahan • Reputation: 2,366

AJANTPHARM - chart - 337518
Ajantapharma trading around MA 50 level & trendline, both levels hs bn acting as strong Resistance. Price failed multiple times to break above on both levels in the past. Have a close watch if price break above both resistance and sustain there in small time frame. we can expect...
Read more...
1
reply
Reply
@DVSTOCKS • Reputation: 196

Ajantapharma looks gud
Like
reply
Reply
@stockmind • Reputation: 16

Given sell at 985 And Tqrget 960(safe target) Achieved
🤑🤑🤑
Stock made low of 917 from 985 🤑🤑🤑🤑
AJANTPHARM - 296815
Like
reply
Reply
@newsbot • Reputation: 1,933
Hold Ajanta Pharmaceuticals; target of Rs 1010: ICICI Direct
ICICI Direct recommended hold rating on Ajanta Pharmaceuticals with a target price of Rs 1010 in its research report dated August August 01, 2019.
moneycontrol.com
Like
reply
Reply
@stockmind • Reputation: 16

GIVEN sell Call At 908 And Target 895(made low of 883)
AJANTPHARM - 294564
Like
reply
Reply
@newsbot • Reputation: 1,933
Stocks in the news: Zee Entertainment, Eicher Motors, Wipro, Ashok Leyland, HDFC
Eicher Motors | Wipro | Ashok Leyland | IndiaMart InterMesh | Unichem Labs and Ajanta Pharma are stocks which are in the news today.
www.moneycontrol.com
Like
reply
Reply
@newsbot • Reputation: 1,933
Stocks in the news: Zee Entertainment, Eicher Motors, Wipro, Ashok Leyland, IndiaMart
Eicher Motors | Wipro | Ashok Leyland | IndiaMart InterMesh | Unichem Labs and Ajanta Pharma are stocks which are in the news today.
www.moneycontrol.com
Like
reply
Reply
@newsbot • Reputation: 1,933
Ajanta Pharma Standalone June 2019 Net Sales at Rs 545.74 crore, up 23.48% Y-o-Y
moneycontrol.com
Like
reply
Reply
@newsbot • Reputation: 1,933
Ajanta Pharma Consolidated June 2019 Net Sales at Rs 611.94 crore, up 19.76% Y-o-Y
moneycontrol.com
Like
reply
Reply
@newsbot • Reputation: 1,933
Like
reply
Reply
@newsbot • Reputation: 1,933
Like
reply
Reply
@ArrowMoney • Reputation: 2,645
Arrowmoney in AJANTPHARM
Ajanta Pharma Clear Down trend Resistance on Weekly chart Ready to Break Weekly Support Line 900 ...

Ajanta Pharma
Broken 900 & sustaining
May lead to 820-790-745-688 🔴
Like
reply
Reply
@ArrowMoney • Reputation: 2,645

Ajanta Pharma
Clear Down trend Resistance on Weekly chart
Ready to Break Weekly Support Line 900
Once close below 900 can lead more pain till 820-790-745-688 🔴
Cautious view: Do not try to Bottom Fishing here.
Disclaimer: All the Recommendation/View Given in Arrowmoney are only ...
Read more...
Like
reply
Reply

BOUGHT AJANTApharma @ 959-960 sl 0.5%
Like
reply
Reply

TURTLE INTRADAY sold ajantpharm @ 954-955 sl 0.5%
Like
reply
Reply (1)
Latest replies

🐢🐢🐢 TURTLE INTRADAY sold #ajantpharm @ 954-955 sl 0.5%
till now ............................*948*

sold #ajantpharm @ 956-954 sl 0.5%
Like
reply
Reply (1)
Latest replies

#ajantapharm.......... till now 928 #turtlestrategy
@newsbot • Reputation: 1,933
Like
reply
Reply
MILLIONAIREE CAPITAL in AJANTPHARM
Buy ajanthpharma at 950-956 Sl 938 Target 997/1010 Buy 2 lots Intraday

Finally ajanthpharma hitn967++++🤑💃💥💃💃💃💥💥
Like
reply
Reply
MILLIONAIREE CAPITAL in AJANTPHARM
Buy ajanthpharma at 950-956 Sl 938 Target 997/1010 Buy 2 lots Intraday

Now moving atv966++++🤑🤩💃💃💃🤑🤩💃💃💃💃🍾🍾🍾🤩
Like
reply
Reply
MILLIONAIREE CAPITAL in AJANTPHARM
Buy ajanthpharma at 950-956 Sl 938 Target 997/1010 Buy 2 lots Intraday

Ajanthpharma moving above 964+++💃💃🤩💃🤑💃🤩🤑🤩🤑
Like
reply
Reply
MILLIONAIREE CAPITAL in AJANTPHARM
Buy ajanthpharma at 950-956 Sl 938 Target 997/1010 Buy 2 lots Intraday

Ajanthpharma flying from 951 ....to now tarding at 961+++💸🚀💥💵💃💸💥💃🚀💃💵💃🚀💥🚀💥🚀💃🚀💵💃💃
Safe traders book profit
951 - 961= 10 points *(2 lots)1000
Profit Rs.10000+++💃💵💥💵💥💃🤩💃🤩💃🤩💵🤩💵💸🚀💸💸🚀💸💃🤩💃🤩💵💸💵💸💸💵🤩💃💵🤩💵💸
1
reply
Reply

AJANTAPHARMA NSE CASH SELL BELOW 954 FOR TARGET 946 - 940
Like
reply
Reply
@tradingfab • Reputation: 720

26-06-19
AJANTPHARM SELL FUT JUN (Intraday)
only Below @ 955
SL 962
TGT 952, 949, 945
Like
reply
Reply (1)
Latest replies
Sameer  @tradingfab
Jun 26 3:37 PM

** Hit 1st TGT 952 **
MILLIONAIREE CAPITAL in AJANTPHARM
Buy ajanthpharma at 950-956 Sl 938 Target 997/1010 Buy 2 lots Intraday

Activated 👍👍👍
Like
reply
Reply

Buy ajanthpharma at 950-956
Sl 938
Target 997/1010
Buy 2 lots
Intraday
Like
reply
Reply
@commodityBiz • Reputation: 3,346

SELL AJANTPHARM FUT JUN AT 957 STRICT SL 968 SAFE TRGT 940 TRGT 938
Like
reply
Reply
@tmtview • Reputation: 820

AJANTPHARM - chart - 224574
(TMT) AJANTA PHARMA (958) FORMING HARMONIC PATTERN SEA PONY, INDICATING REVERSAL, AS PER PATTERN TGT 1030-1080 ENTRY POINT 940 AROUND S/L 920 BELOW....
Like
reply
Reply
@100billionclub • Reputation: 3,836

FNO: SELL AJANTPHARM BELOW 977 SL 989 TGT 962 - 955. CMP: 977
Like
reply
Reply (1)
@commodityBiz • Reputation: 3,346

SELL AJANTPHARM FUT AT 999 STRICT SL 1007 TARGET 980
Like
reply
Reply
  • AJANTPHARM - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization9,036.61
    Enterprise Value9,000.74
    Price to Earnings29.08
    Price to Book Value4.22
    Return on Capital Employed0.29
    Return on Equity0.22
    Face Value2
    Dividend YieldNA
  • AJANTPHARM Share Price - Technicals

    keyboard_arrow_down
    AJANTPHARM - 52 Week High₹1,211
    AJANTPHARM - 52 Week Low₹825
  • AJANTPHARM - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    1-Aug-19ICICIdirect.comHold1,010
    2-Feb-19Reliance SecuritiesBuy1,225
    1-Feb-19ICICIdirect.comBuy1,100
    31-Jan-19Motilal OswalBuy1,390
    1-Aug-18Motilal OswalBuy1,560
    AJANTPHARM Brokerage Price Target
  • AJANTPHARM Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jan 22118012001177.051193.5
    Jan 2112031210.511701179.85
    Jan 20113512111130.251195.6
    Jan 17112811711115.151136.85
    Jan 161083.511371083.51128.6
  • AJANTPHARM Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹1,044.8
    30 Day Moving Average₹1,019.28
    50 Day Moving Average₹1,007.5
    100 Day Moving Average₹1,010.14
    200 Day Moving Average₹997.26
  • AJANTPHARM - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue1,830.451,822.710
    Operating Profit546.81636.01-0.14
    Profit Before Tax562.44640.65-0.12
    Net Income427.52499.81-0.14
  • AJANTPHARM - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds2,1431,931.50.11
    Total Liabilities379381.35-0.01
    Total Assets2,5222,312.850.09
  • AJANTPHARM - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity219.16529.06-0.59
    Cash from Investing Activity-201.12-349.66-0.42
    Cash from Financing Activity-0.54-194.08-1
    Net Cash Flow17.5-14.68-2.19
  • AJANTPHARM - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.180.29
    Return on Equity0.220.33
    Return on Capital Employed0.290.43
  • AJANTPHARM - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.35
    3 Year CAGR Growth in Operating Profit0.17
    3 Year CAGR Growth in EBIDTA0.24
    3 Year CAGR Growth in Net Income0.4
    3 Yr CAGR Growth - Diluted EPS0.39
  • AJANTPHARM - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue1.18
    5 Year CAGR Growth in Operating Profit1.64
    5 Year CAGR Growth in EBIDTA1.89
    5 Year CAGR Growth in Net Income3.23
    3 Yr CAGR Growth - Diluted EPS0.12
  • AJANTPHARM - Recent News

    keyboard_arrow_down
    NewsBot
    Sep 26 12:28 AM
    GSK suspends Ranitidine distribution in India, regulators seek drug testing data from pharma cos
    Moneycontrol
    NewsBot
    Sep 18 11:53 PM
    link
    Avoid Aurobindo Pharma: Pritesh Mehta
    Moneycontrol
    NewsBot
    Sep 14 5:58 PM
    SBI, Ceat among 4 stocks brokerages are betting on for handsome gains — Here's why
    Moneycontrol
    NewsBot
    Aug 2 4:48 PM
    Hold Ajanta Pharmaceuticals; target of Rs 1010: ICICI Direct
    moneycontrol.com
    NewsBot
    Aug 1 1:53 PM
    Stocks in the news: Zee Entertainment, Eicher Motors, Wipro, Ashok Leyland, HDFC
    www.moneycontrol.com
    NewsBot
    Aug 1 1:08 PM
    Stocks in the news: Zee Entertainment, Eicher Motors, Wipro, Ashok Leyland, IndiaMart
    www.moneycontrol.com
    NewsBot
    Jul 31 11:33 PM
    Ajanta Pharma Standalone June 2019 Net Sales at Rs 545.74 crore, up 23.48% Y-o-Y
    moneycontrol.com
    NewsBot
    Jul 31 11:33 PM
    Ajanta Pharma Consolidated June 2019 Net Sales at Rs 611.94 crore, up 19.76% Y-o-Y
    moneycontrol.com
    NewsBot
    Jul 20 3:33 AM
    NewsBot
    Jul 19 3:38 PM
  • AJANTPHARM - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. S...
    Aurobindo Pharma Ltd. Sector: Pharma...
    Biocon Ltd. Sector: Pharmaceuticals ...
    Cipla Ltd. Sector: Pharmaceuticals a...
    Lupin Ltd. Sector: Pharmaceuticals an...
    Dr. Reddy's Laboratories Ltd. Sector...
    Piramal Enterprises Ltd. Sector: Phar...
    Glenmark Pharmaceuticals Ltd. Sector...
    Divi's Laboratories Ltd. Sector: Pha...
    Strides Pharma Science Ltd. Sector: P...
  • AJANTPHARM - More Information

    keyboard_arrow_down

    Ajanta Pharma Limited:
    Ajanta Pharma Limited is among the nation’s most prestigious pharmaceutical company, announcing their mission to serve the global healthcare with empathy, innovation and technology. The firm was established in the year of 1973 with headquarter at Mumbai. The company is announcing to ‘Serve Healthcare Needs Worldwide’. The company is aiming to use cutting edge technology to bring innovations.
    The company is developing its business internationally to achieve their aim. The company is currently pursuing its business in India, USA and around thirty other countries in Asia, Africa, CIS and the Middle East. With a Research and Development team enriched with more than 750 scientists, Ajanta Pharma is possessing a workforce of more than 7,500 employees all over the world. The company has currently 1,400 products in different countries around the globe with a deep focus on the market of USA, expecting a good outcome. Ajanta Pharma has been manufacturing anti-malarial products for the health programmes in Africa approved by WHO.
    Company Information:
    Soon after its inception in 1973, Ajanta Pharma Limited has been pursuing tremendous achievements in its journey towards the golden jubilee. In 1979, the company produced branded ‘Over The Counter’ products along with developing its first manufacturing facility set-up at Chikalthana, India. By seven years the firm set up its second manufacturing facility at Paithan, India. By 1989, Ajanta Pharma reached a milestone of manufacturing more than 30 ‘Over The Counter’ products. The company intervened the international market for the first time in 1992. In 1995 the company developed its subsidiary at Mauritius with a manufacturing facility set-up. Millennium brought a credible achievement for the company while Ajanta Pharma had been enlisted in National Stock Exchange and Bombay Stock Exchange. The company intervened the domestic prescription market in 2002, introducing speciality segment force.
    As the company has been in the process of in traducing innovations, it developed its R&D facility at Kandivli. Establishing an Active Pharmaceutical Ingredient (API) Plant at Waluj in Aurangabad, the company got the approval of USFDA in 2007. In the same year, Ajanta Pharma developed a manufacturing facility in Aurangabad for rapid growth. The company received its international recognition in the same year by becoming the world’s first generic company to achieve WHO Geneva Pre-qualification for Anti-Malarial Drug. In 2010, Ajanta Pharma intervened the market of the Philippines through Ajanta Philippines Inc. Ophthalmology, Dermatology, Cardiology— these are the three segments where the company created its reign and emerged in the leading position in 2011.
    In the next year, the company achieved its place among the top ten pharmaceutical companies in Franco Africa. The company started its journey to explore the USA market in the year 2013. Ajanta Pharma inaugurated its Research & Development centre at Kandivli, Mumbai to expand its innovations and after that the business in a larger periphery. Inauguration of a new facility was done in Dahej, 2015 to fulfil the requirements of the USA market and WHO. Montelukas Sodium Oral Granules were announced to launch by Ajanta in 2015 along with the announcement of the launch of Montelukast IR Tablets and Montelukast Chewable Tablets in the US market. In the year 2017, the company developed its new facility in Guwahati. In the same year, USFDA has approved Ajanta Pharma’s Dahej facility.
    The company is currently spending 9% of its revenue in Research & Development in the financial year of 2019-20. From 28 different nationalities, the company has appointed more than 7500 people as its permanent staff. The total income in the fiscal year of 2019-20 is 2076 crore INR; the company has been enjoying a net profit of 387 crore INR in the same financial year. The current EBITDA margin of the company in the current fiscal year of 2019-20 is 28%.
    The company is announcing its philosophy as first to create opportunities and then optimize them on fullest.
    How Ajanta Pharma Ltd, is categorised as Pharmaceuticals and Health Care Sector, and Pharmaceuticals Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Ajanta Pharma Ltd is categorized under the Pharmaceutical and Health care sector and Pharmaceutical Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Ajanta Pharma Ltd, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.